Evolus, Inc. (EOLS)
NGM · Healthcare · Drug Manufacturers - Specialty & Generic
$6.73
+3.38%
Closing price as of 2026-06-12 · Source: TEK2day Finance
Key Metrics
Market Cap
$443.2M
Shares Outstanding
65.9M
P/S (TTM)
1.5x
Exchange
NGM
Currency
USD
About Evolus, Inc.
Evolus, Inc., a performance beauty company, delivers products in the cash-pay aesthetic market in the United States, Canada, Europe, and Australia. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults; and Evolysse, a collection of injectable hyaluronic acid gels, which includes various products, such as mid face, nasolabial folds, lips and eyes. The company was incorporated in 2012 and is headquartered in Newport Beach, California.
Quarterly Financials
| Metric | 2025-06-30 | 2025-09-30 | 2025-12-31 | 2026-03-31 |
|---|---|---|---|---|
| Revenue | 69.4M | 69.0M | 90.3M | 73.1M |
| Gross Profit | 45.3M | 45.8M | 59.3M | 48.9M |
| Operating Income | -14.1M | -10.2M | -291K | -6.9M |
| Net Income | -17.1M | -15.7M | 130K | -10.7M |
| Diluted EPS | $-0.27 | $-0.24 | $0.00 | $-0.16 |
Annual Financials
| Metric | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|---|
| Revenue | 148.6M | 202.1M | 266.3M | 297.2M |
| Gross Profit | 89.8M | 137.6M | 182.3M | 197.1M |
| Operating Income | -59.6M | -45.0M | -27.2M | -37.6M |
| Net Income | -74.4M | -61.7M | -50.4M | -51.6M |
| Diluted EPS | $-1.33 | $-1.08 | $-0.81 | $-0.80 |